Evidence for anti-inflammatory effects of exercise in CKD

Journal of the American Society of Nephrology

Volumn 25, Issue 9, 2014, Pages 2121-2130

  Viana, João L ^a   Kosmadakis, George C ^b   Watson, Emma L ^c   Bevington, Alan ^c   Feehally, John ^b   Bishop, Nicolette C ^a   Smith, Alice C ^b,c  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD69 ANTIGEN; CD86 ANTIGEN; ELASTASE; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR RECEPTOR; AUTACOID; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AEROBIC EXERCISE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY MASS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION; EXERCISE INTENSITY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KINESIOTHERAPY; LEUKOCYTE COUNT; MALE; MONOCYTE; NEUTROPHIL; NEUTROPHIL COUNT; PROTEIN EXPRESSION; PROTEINURIA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREADMILL EXERCISE; WALKING; AGED; BLOOD; EXERCISE; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

AGED; C-REACTIVE PROTEIN; EXERCISE; EXERCISE THERAPY; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MONOCYTES; NEUTROPHIL ACTIVATION; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RENAL INSUFFICIENCY, CHRONIC; T-LYMPHOCYTES; WALKING;

EID: 84920033664     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013070702     Document Type: Article

References (83)

1. Descamps-Latscha B, Jungers P, Witko-Sarsat V: Immune system dysregulation in uremia: Role of oxidative stress. Blood Purif 20: 481-484, 2002
2. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I: Disturbances of acquired immunity in hemodialysis patients. SeminDial 20: 440-451, 2007
3. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B: Aspects of immune dysfunction in end-stage renal disease. Clin J AmSoc Nephrol 3: 1526-1533, 2008
4. Naqvi SB, Collins AJ: Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 13: 199-204, 2006
5. Saran AM, DuBose TD Jr.: Cardiovascular disease in chronic kidney disease. Ther Adv Cardiovasc Dis 2: 425-434, 2008
6. Dalrymple LS, Go AS: Epidemiology of acute infections among patients with chronic kidney disease.Clin JAmSoc Nephrol 3: 1487-1493, 2008
7. Stenvinkel P: Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease. J Intern Med 268: 456-467, 2010
8. Petersen AMW, Pedersen BK: The anti-inflammatory effect of exercise. J Appl Physiol (1985) 98: 1154-1162, 2005
9. Senchina DS, Kohut ML: Immunological outcomes of exercise in older adults. Clin Interv Aging 2: 3-16, 2007
10. Haaland DA, Sabljic TF, BaribeauDA, Mukovozov IM, Hart LE: Is regular exercise a friend or foe of the aging immune system? A systematic review. Clin J Sport Med 18: 539-548, 2008
11. Beavers KM, Brinkley TE, Nicklas BJ: Effect of exercise training on chronic inflammation. Clin Chim Acta 411: 785-793, 2010
12. Nieman D: Moderate exercise improves immunity and decreases illnesss rates. Am J Lifestyle Med 5: 338-345, 2011
13. Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA: The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 11: 607-615, 2011
14. Bronas UG: Exercise training and reduction of cardiovascular disease risk factors in patients with chronic kidney disease. Adv Chronic Kidney Dis 16: 449-458, 2009
15. Heiwe S, Jacobson SH: Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 10: CD003236, 2011
16. Kosmadakis GC, Bevington A, Smith AC, Clapp EL, Viana JL, Bishop NC, Feehally J: Physical exercise in patients with severe kidney disease. Nephron Clin Pract 115: c7-c16, 2010
17. Johansen KL, Painter P: Exercise in individuals with CKD. Am J Kidney Dis 59: 126-134, 2012
18. Gleeson M: Immune function in sport and exercise. J Appl Physiol (1985) 103: 693-699, 2007
19. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA, Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-Goetz L, Rogers CJ, Northoff H, Abbasi A, Simon P: Position statement. Part one: Immune function and exercise. Exerc Immunol Rev 17: 6-63, 2011
20. Kosmadakis GC, John SG, Clapp EL, Viana JL, Smith AC, Bishop NC, Bevington A, Owen PJ, McIntyre CW, Feehally J: Benefits of regular walking exercise in advanced pre-dialysis chronic kidney disease. Nephrol Dial Transplant 27: 997-1004, 2012
21. Castaneda C, Gordon PL, Parker RC, Uhlin KL, Roubenoff R, Levey AS: Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 43: 607-616, 2004
22. Leehey DJ, Moinuddin I, Bast JP, Qureshi S, Jelinek CS, Cooper C, Edwards LC, Smith BM, Collins EG: Aerobic exercise in obese diabetic patients with chronic kidney disease: A randomized and controlled pilot study. Cardiovasc Diabetol 8: 62, 2009
23. Headley S, Germain M, Milch C, Pescatello L, Coughlin MA, Nindl BC, Cornelius A, Sullivan S, Gregory S, Wood R: Exercise training improves HR responses and VO2peak in predialysis kidney patients. Med Sci Sports Exerc 44: 2392-2399, 2012
24. McCarthy DA, Grant M, Marbut M, Watling M, Wade AJ, Macdonald I, Nicholson S, MelsomRD, Perry JD: Brief exercise induces an immediate and a delayed leucocytosis. Br J Sports Med 25: 191-195, 1991
25. Nieman DC, Miller AR, Henson DA, Warren BJ, Gusewitch G, Johnson RL, Davis JM, Butterworth DE, Herring JL, Nehlsen-Cannarella SL: Effect of high-versus moderate-intensity exercise on lymphocyte subpopulations and proliferative response. Int J Sports Med 15: 199-206, 1994
26. Nieman DC, Henson DA, AustinMD, Brown VA: Immune response to a 30-minute walk. Med Sci Sports Exerc 37: 57-62, 2005
27. Peake JM: Exercise-induced alterations in neutrophil degranulation and respiratory burst activity: Possible mechanisms of action. Exerc Immunol Rev 8: 49-100, 2002
28. Sela S, Shurtz-Swirski R, Cohen-MazorM, Mazor R, Chezar J, ShapiroG, Hassan K, Shkolnik G, Geron R, Kristal B: Primed peripheral polymorphonuclear leukocyte: A culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 16: 2431-2438, 2005
29. Cohen G, Haag-Weber M, Hörl WH: Immune dysfunction in uremia. Kidney Int Suppl 62: S79-S82, 1997
30. Chonchol M: Neutrophil dysfunction and infection risk in end-stage renal disease. Semin Dial 19: 291-296, 2006
31. Fischer CP: Interleukin-6 in acute exercise and training: What is the biological relevance? Exerc Immunol Rev 12: 6-33, 2006
32. Pedersen BK, Febbraio MA: Muscle as an endocrine organ: Focus on muscle-derived interleukin-6. Physiol Rev 88: 1379-1406, 2008
33. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M: IL-10, IL-6, and TNFalpha: Central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 67: 1216-1233, 2005
34. Steensberg A, van Hall G, Osada T, Sacchetti M, Saltin B, Klarlund Pedersen B: Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529: 237-242, 2000
35. Toft AD, Falahati A, Steensberg A: Source and kinetics of interleukin-6 in humans during exercise demonstrated by a minimally invasive model. Eur J Appl Physiol 111: 1351-1359, 2011
36. Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, Febbraio M, Saltin B: Searching for the exercise factor: Is IL-6 a candidate? J Muscle Res CellMotil 24: 113-119, 2003
37. Kasapis C, Thompson PD: The effects of physical activity on serum Creactive protein and inflammatory markers: A systematic review. J Am Coll Cardiol 45: 1563-1569, 2005
38. Plaisance EP, Grandjean PW: Physical activity and high-sensitivity C-reactive protein. Sports Med 36: 443-458, 2006
39. Costa E, Rocha S, Rocha-Pereira P, Nascimento H, Castro E, Miranda V, Faria MS, Loureiro A, Quintanilha A, Belo L, Santos-Silva A: Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Am J Nephrol 28: 935-940, 2008
40. Caimi G, Carollo C, Montana M, Vaccaro F, Lo Presti R: Elastase, myeloperoxidase, nitric oxide metabolites and oxidative status in subjects with clinical stable chronic renal failure on conservative treatment. Clin Hemorheol Microcirc 43: 253-258, 2009
41. Polańska B, Augustyniak D, Makulska I, Niemczuk M, Zwolińska D, Jankowski A: Elastase, a1-proteinase inhibitor, and interleukin-8 in predialyzed and hemodialyzed patients with chronic kidney disease. Pediatr Int 52: 735-743, 2010
42. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P, : Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 154: 882-892, 1995
43. Meier P, Dayer E, Blanc E, Wauters J-P: Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J Am Soc Nephrol 13: 204-212, 2002
44. Moser B, Roth G, Brunner M, Lilaj T, Deicher R, Wolner E, Kovarik J, Boltz-Nitulescu G, Vychytil A, Ankersmit HJ: Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: A comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. BiochemBiophys Res Commun 308: 581-585, 2003
45. Litjens NHR, van Druningen CJ, Betjes MGH: Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol 118: 83-91, 2006
46. Meier P, Dayer E, Ronco P, Blanc E: Dysregulation of IL-2/IL-2R system alters proliferation of early activated CD4+ T cell subset in patients with end-stage renal failure. Clin Nephrol 63: 8-21, 2005
47. Meier P, Spertini F, Blanc E, Burnier M: Oxidized low-density lipoproteins activate CD4+ T cell apoptosis in patients with end-stage renal disease through Fas engagement. J Am Soc Nephrol 18: 331-342, 2007
48. Ankersmit HJ, Deicher R, Moser B, Teufel I, Roth G, Gerlitz S, Itescu S, Wolner E, Boltz-Nitulescu G, Kovarik J: Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol 125: 142-148, 2001
49. FlynnMG, McFarlin BK: Toll-like receptor 4: Link to the anti-inflammatory effects of exercise? Exerc Sport Sci Rev 34: 176-181, 2006
50. Gleeson M, McFarlin B, FlynnM: Exercise and Toll-like receptors. Exerc Immunol Rev 12: 34-53, 2006
51. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 21: 335-376, 2003
52. Timmerman KL, Flynn MG, Coen PM, Markofski MM, Pence BD: Exercise training-induced lowering of inflammatory (CD14+CD16+) monocytes: A role in the anti-inflammatory influence of exercise? J Leukoc Biol 84: 1271-1278, 2008
53. Ziegler-Heitbrock L: The CD14+ CD16+ blood monocytes: Their role in infection and inflammation. J Leukoc Biol 81: 584-592, 2007
54. Girndt M, Köhler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Büschenfelde KH, Fleischer B: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 47: 559-565, 1995
55. Girndt M, Sester U, Kaul H, Köhler H: Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a singlecell level. J Am Soc Nephrol 9: 1689-1696, 1998
56. Morita Y, Yamamura M, Kashihara N, Makino H: Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. Res Commun Mol Pathol Pharmacol 98: 19-33, 1997
57. Higuchi T, Yamamoto C, Kuno T, Mizuno M, Takahashi S, Kanmatsuse K: Increased production of interleukin-1beta and interleukin-1 receptor antagonist by peripheral blood mononuclear cells in undialyzed chronic renal failure. Nephron 76: 26-31, 1997
58. Sardenberg C, Suassuna P, Watanabe R, Cruz Andreoli MC, Aparecida Dalboni M, Faria Seabra V, Draibe SA, Cendoroglo Neto M, Jaber B: Balance between cytokine production by peripheral blood mononuclear cells and reactive oxygen species production by monocytes in patients with chronic kidney disease. Ren Fail 26: 673-681, 2004
59. Meier P, Meier R, Blanc E: Influence of CD4+/CD25+ regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Rev Cardiovasc Ther 6: 987-997, 2008
60. Meier P, von Fliedner V, Markert M, van Melle G, Deppisch R, Wauters JP:One-year immunological evaluation of chronic hemodialysis in endstage renal disease patients. Blood Purif 18: 128-137, 2000
61. Stachowski J, Pollok M, Burrichter H, Baldamus CA: Immunodeficiency in ESRD-patients is linked to altered IL-2 receptor density on T cell subsets. J Clin Lab Immunol 34: 171-177, 1991
62. Stenvinkel P, Bárány P, Heimbürger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD:What is the role of interleukin-6? Kidney Int Suppl 80: 103-108, 2002
63. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke H-D, Tribouilloy C, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox): Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77: 550-556, 2010
64. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765, 2001
65. Seyrek N, Karayaylali I, Balal M, Paydas S, Aikimbaev K, Cetiner S, Seydaoglu G: Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients? Scand J Urol Nephrol 39: 405-409, 2005
66. Girndt M, Sester U, Sester M, Deman E, Ulrich C, Kaul H, Köhler H: The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int 60: 2385-2391, 2001
67. GirndtM, Kaul H, Sester U, Ulrich C, Sester M, Georg T, Köhler H: Antiinflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 62: 949-955, 2002
68. BrockhausM: Soluble TNF receptor: What is the significance? Intensive Care Med 23: 808-809, 1997
69. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA: Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45: 890-896, 1994
70. Church TS, EarnestCP, Thompson AM, Priest EL, Rodarte RQ, Saunders T, Ross R, Blair SN: Exercise without weight loss does not reduce Creactive protein: The INFLAME study. Med Sci Sports Exerc 42: 708-716, 2010
71. Lacson E Jr, Levin NW: C-reactive protein and end-stage renal disease. Semin Dial 17: 438-448, 2004
72. Wanner C, Drechsler C, Krane V: C-reactive protein and uremia. Semin Dial 22: 438-441, 2009
73. Wetmore JB, LovettDH, HungAM, Cook-WiensG, Mahnken JD, Sen S, Johansen KL: Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) 13: 593-600, 2008
74. Pachaly MA, do Nascimento MM, Suliman ME, Hayashi SY, Riella MC, Manfro RC, Stenvinkel P, Lindholm B: Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. Blood Purif 26: 204-210, 2008
75. Zoccali C, Tripepi G, Mallamaci F: Dissecting inflammation in ESRD: Do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 17[Suppl 3]: S169-S173, 2006
76. Honda H, Qureshi AR, Heimbürger O, Bárány P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B: Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47: 139-148, 2006
77. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 16[Suppl 1]: S83-S88, 2005
78. Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911, 1999
79. Borg GA: Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14: 377-381, 1982
80. Dill DB, Costill DL: Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol 37: 247-248, 1974
81. Atkinson G: Analysis of repeated measurements in physical therapy research. Phys Ther Sport 2: 194-208, 2001
82. Cohen JW: Statistical Power Analysis for the Behavioral Sciences, 2nd Ed., Hillsdale, NJ, Lawrence Erlbaum Associates, 1988
83. Hedges LV: Distributional theory for Glass's estimator of effect size and related estimators. J Educ Stat 6: 107-128, 1981